Stockholders Approve 3.8M Share Increase to Equity Incentive Plan and Officer Exculpation

summarizeSummary

Precision BioSciences stockholders approved an increase of 3.8 million shares to its equity incentive plan, representing significant potential dilution, and also approved an amendment to exculpate officers from certain liabilities.

check_boxKey Events · Corporate Governance and Compliance · DTIL

• Equity Incentive Plan Expanded

  Stockholders approved an amendment to the 2019 Incentive Award Plan, increasing the number of shares available for issuance by an additional 3,800,000 shares. This follows the company seeking approval for this expansion in a DEF 14A filing on April 8, 2026.

• Officer Exculpation Approved

  An amendment to the Certificate of Incorporation was approved, providing for the exculpation of certain officers from liability as permitted by Delaware law. This change became effective on May 22, 2026.

• Annual Meeting Results

  All proposals at the annual meeting on May 21, 2026, were approved, including the election of two Class I directors (Melinda Brown and Geno Germano), ratification of the independent auditor, and advisory approval of executive compensation.

auto_awesomeAnalysis · DTIL · Life Sciences

Stockholders approved a significant expansion of the company's equity incentive plan, adding 3.8 million shares for future awards. This represents a substantial potential dilution of approximately 14.7% based on the current market capitalization, which will impact existing shareholders. Additionally, an amendment to the Certificate of Incorporation was approved to exculpate certain officers from liability, a corporate governance change that reduces accountability.